Paul M. Ness

Hemanext, Inc. develops blood storage systems. Its technology includes anaerobic storage, background on stored blood, science of storage lesion, and clinical implications. The company was founded by Martin A. Cannon and is headquartered in Lexington, MA.

The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage.

The American Association of Blood Banks is a professional organization dedicated to advancing the field of transfusion medicine and cellular therapies. The non-profit company is based in Bethesda, MD and has subsidiaries in Puerto Rico. The association provides accreditation and certification programs for blood banks and transfusion services, as well as educational resources and advocacy efforts.